Tag: igital Transformation

Digital CMC Consortium Targets Pharmaceutical Development Challenges

Leading pharmaceutical and technology companies have launched the Digital CMC Consortium to accelerate digital transformation across pharmaceutical development and manufacturing. The initiative aims to remove persistent data and workflow barriers across the drug development lifecycle.The not-for-profit consortium includes Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship’s Pioneering Medicines, Stellix, ZS Associates and QbDVision. Together, these organisations aim to establish practical digital standards for Chemistry, Manufacturing and Controls (CMC).CMC covers the processes used to develop, manufacture, test and control pharmaceutical products. However, many companies still rely on manual tasks, disconnected software and document-heavy workflows. These limitations can slow technology transfer, increase duplicated work and complicate regulatory documentation.The consortium plans to address these challenges through interoperable digital infrastructure. Its approach focuses on structured data, reusable information and consistent workflows across pharmaceutical companies and manufacturing partners.

Novartis Promotes Collaborative Digital Standards

The Digital CMC Consortium follows a pre-competitive collaboration model. Members work together on shared technical challenges instead of independently building solutions for the same problems.Moreover, the initiative combines existing industry guidelines with new standards where current practices leave gaps. Members are also developing software tools and code to turn these standards into practical digital workflows.Achim Frauenschuh, Co-Chair of the Digital CMC Consortium and Associate Director of Science and Technology Drug Substance Development at Novartis, highlighted the value of shared expertise. He explained that collective investment can help companies access structured data models, standardised templates and implementation guidance.This collaborative approach can reduce duplicated development costs and simplify digital adoption. In addition, common standards can help pharmaceutical organisations improve data consistency across development, manufacturing and quality operations.For industrial automation providers, this direction highlights the growing importance of interoperability. PLC, DCS and manufacturing execution systems generate operational data that can support digital workflows when companies establish consistent data structures and integration methods.

Digital Technology Transfer Becomes a Priority

After its first year of collaboration and proof-of-concept activities, the consortium is shifting its attention towards wider industry adoption. Its initial priority is digital technology transfer between pharmaceutical sponsors and contract development and manufacturing organisations (CDMOs).Technology transfer requires teams to exchange process knowledge, manufacturing instructions, analytical methods and other technical information. Traditional document-based approaches can create delays when different organisations use incompatible formats or disconnected systems.The consortium aims to convert static documents into structured digital information that teams can reuse. Consequently, pharmaceutical manufacturers could improve information exchange between development laboratories, production facilities and external manufacturing partners.Mike Stapleton, Chairman of the Digital CMC Consortium and Chief Business Officer at QbDVision, emphasised the opportunity to extend digital transformation beyond drug discovery and clinical trials. He identified CMC as another area where digital tools can improve how companies develop and deliver therapies.Global supply chains add further complexity. Therefore, manufacturers need consistent information models that support communication across sites, partners and technology platforms.

Industrial Automation Supports Connected Pharmaceutical Manufacturing

Digital CMC initiatives also align with wider developments in industrial automation and pharmaceutical factory automation. Manufacturers increasingly connect process equipment, control systems and digital applications to improve production visibility and data management.Programmable logic controllers (PLCs) manage machine sequences, equipment interlocks and discrete operations. Distributed control systems (DCS) coordinate continuous processes, monitor process variables and support operator supervision.When integrated with manufacturing execution systems and data management platforms, these technologies can provide structured production information. However, successful integration depends on suitable data models, system interfaces and governance practices.The Digital CMC Consortium focuses on common digital standards rather than promoting a specific PLC, DCS or software platform. Nevertheless, its work could support more consistent information exchange between pharmaceutical engineering teams and manufacturing systems.This connection matters because technology transfer often requires teams to reconcile process documentation with actual production requirements. Structured digital information can help reduce manual reconciliation and improve traceability throughout the manufacturing lifecycle.

AI and Digital Twins Shape the Future of CMC

The consortium's longer-term roadmap extends beyond technology transfer. Planned areas include knowledge management, automated content creation, digital twins and artificial intelligence.These capabilities could help pharmaceutical companies reuse technical knowledge across development, scale-up and commercial manufacturing. For example, structured process information can provide a foundation for digital twins that represent manufacturing equipment or production processes.AI tools may also assist with technical document preparation and information retrieval. However, pharmaceutical organisations must maintain appropriate validation, data governance and human oversight for regulated activities.Digital twins and AI also depend on trustworthy data from engineering and production systems. As a result, consistent information standards can support future applications across industrial automation, process control and pharmaceutical manufacturing.The consortium also aims to present a coordinated industry perspective when engaging with health authorities. Common approaches could help companies align internal technical documentation with regulatory submission requirements.

Rockwell Automation Contributes Life Sciences Expertise

Rockwell Automation is contributing its industrial automation and life sciences expertise to the consortium. Its participation brings manufacturing technology knowledge into a collaboration that also includes pharmaceutical companies and specialist software providers.Matt Weaver, Vice President of Global Industry – Life Sciences at Rockwell Automation, highlighted the need to change working practices alongside technology adoption. His comments reflect a broader industry shift towards connected processes and more consistent information exchange.For pharmaceutical manufacturers, digital transformation involves more than installing new software. Teams must also align engineering practices, data governance, quality processes and system integration strategies.Industrial automation technologies can support this transition by connecting production equipment with higher-level manufacturing and information systems. However, organisations must assess interoperability, cybersecurity and regulatory requirements before implementing new connections.

Digital CMC Standards Could Improve Pharmaceutical Operations

The Digital CMC Consortium aims to establish shared digital foundations for pharmaceutical development and manufacturing. Its immediate focus on technology transfer addresses a practical challenge across sponsor companies and CDMOs.Over time, structured information and interoperable systems could reduce duplicated work and improve technical consistency. Furthermore, digital twins, AI and automated documentation may create additional opportunities for process knowledge reuse.The results will depend on industry adoption, implementation quality and alignment with regulatory expectations. Even so, the initiative highlights an important direction for pharmaceutical manufacturing: combining industrial automation with standardised digital information.For manufacturers, engineering teams and technology providers, the key opportunity lies in connecting operational data with the broader CMC lifecycle. Better information exchange could help organisations manage manufacturing complexity and support the development of new therapies.